<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238860</url>
  </required_header>
  <id_info>
    <org_study_id>AIMS-hep B-123</org_study_id>
    <nct_id>NCT02238860</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis</brief_title>
  <official_title>A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute Of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute Of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents&#xD;
      have been claimed equivalent in treatment, there are no head to head trials available in the&#xD;
      literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed&#xD;
      to compare safety/efficacy and virological response in patients with HBV Decompensated&#xD;
      Cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of entacavir and tenofovir has not been prospectively studied in HBV&#xD;
      Decompensated cirrhosis? This prospective, randomised clinical trial will help us in better&#xD;
      patient management more efficacy and cost effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>EFFICACY ENDPOINTS: EFFICACY ENDPOINTS INCLUDED PLASMA HBV DNA, ALT, HBEAG, HBSAG LOSS AND SEROCONVERION AS WELL AS CTP AND MELD SCORE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>48 weeks</time_frame>
    <description>SAFETY ENDPOINTS: SAFETY ANALYSIS INCLUDED CUMALATIVE RATES ON TREATMENT ADVERSE EVENTS, SEREIOUS ADVERSE EFFECTS DISCONTINUATION DUE TO SIDE EFFECTS,DEATH,HCC,RENAL IMPAIRMENT , HEPATIC FLARE AND DEVELOPMENT OF DRUG RESISTANCE.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>Death</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis Due to Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entacavir 0.5 mg (OD) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300 mg ,OD for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacavir</intervention_name>
    <description>Entacavir-0.5 mg ,OD,for</description>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_label>Tenofovir</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir ,300 mg,OD,for 48 weeks</description>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_label>Tenofovir</arm_group_label>
    <other_name>TDF or PMPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age (18 years- 70 years)&#xD;
&#xD;
          -  Hbv surface antigen positive &gt; 6 months&#xD;
&#xD;
          -  HbeAg (positive or negative both)&#xD;
&#xD;
          -  Hbv DNA 10^3&#xD;
&#xD;
          -  ALT ULN&#xD;
&#xD;
          -  No evidence of HCC&#xD;
&#xD;
          -  Platelets count &gt; 30 thousands&#xD;
&#xD;
          -  CTP score &gt; 7&#xD;
&#xD;
          -  Hepatic encephalopathy (grade 1 - 2 only)&#xD;
&#xD;
          -  No prior Drug resistance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  HCC patients&#xD;
&#xD;
          -  Prior drug resistance&#xD;
&#xD;
          -  Current HE &gt; 2&#xD;
&#xD;
          -  Solid organ transplantation&#xD;
&#xD;
          -  Inadequate hematological function&#xD;
&#xD;
          -  Co infection with hepatitis C and HIV&#xD;
&#xD;
          -  Autoimmune disorders&#xD;
&#xD;
          -  Pregnancy and Breast feeding&#xD;
&#xD;
          -  Other hepatic diseases&#xD;
&#xD;
          -  Patients on immunosuppressant or chemotherapy agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad sadik Memon, Fcps gastro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aims</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr mohammad sadik Memon, Fcps gastro</last_name>
    <phone>022-232593</phone>
    <email>Sadikmemon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madiha Zaki, MSC gastro</last_name>
    <phone>022-232593</phone>
    <email>Madiyaah@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asian Institute of medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Sindh</state>
        <zip>71800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr mohammad sadik Memon, FCPS gastro</last_name>
      <phone>022-232593</phone>
      <email>Sadikmemon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr sadik Memon, FCPS gastro</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Madiha Zaki, MSC gastro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr NANDLAL Serani, FCPS gastro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Umar Soomro, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute Of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohammad sadik memon</investigator_full_name>
    <investigator_title>Professor of gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>Entacavir</keyword>
  <keyword>enofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

